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Background: Lipid accumulation product (LAP) has been advocated as a simple clinical indicator of metabolic
syndrome (MS). However, no studies have evaluated the accuracy of LAP in predicting MS in Taiwanese adults. The
aim of our investigation was to use LAP to predict MS in Taiwanese adults.
Methods: Taiwanese adults aged 50 years and over (n= 513) were recruited from a physical examination center at
a regional hospital in southern Taiwan. MS was defined according to the MS criteria for Taiwanese people. LAP was
calculated as (waist circumference [cm]− 65) × (triglyceride concentration [mM]) for men, and (waist circumference
[cm]− 58) × (triglyceride concentration [mM]) for women. Simple logistic regression and receiver-operating
characteristic (ROC) analyses were conducted.
Results: The prevalence of MS was 19.5 and 21.5% for males and females, respectively. LAP showed the highest
prediction accuracy among adiposity measures with an area under the ROC curve (AUC) of 0.901. This was
significantly higher than the adiposity measure of waist-to-height ratio (AUC= 0.813).
Conclusions: LAP was a simple and accurate predictor of MS in Taiwanese people aged 50 years and over. LAP
had significantly higher predictability than other adiposity measures tested.
Keywords: Adiposity, Chinese, Metabolic syndrome, PredictionBackground
Metabolic syndrome (MS) is a condition that includes
the presence of a cluster of risk factors specific for car-
diovascular disease [1,2], type 2 diabetes mellitus [3],
hypertension [4], and all-cause mortality [5]. Several
diagnostic criteria have evolved since the World Health
Organization task force on diabetes identified insulin
resistance as the dominant cause of MS in 1998 [6].
Over time, several definitions of MS have been pro-
posed, with criteria based on various combinations of
abdominal or visceral obesity, insulin resistance, raised
blood pressure, and dyslipidemia [7]. In Taiwan, the lat-
est definition of MS (MS-TW) recommended by the
Bureau of Health Promotion in the Department of
Health is based on the United States National* Correspondence: m.koo@utoronto.ca
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distribution, and reproduction in any mediumCholesterol Education Program Adult Treatment Panel
III criteria (NCEP ATP III) [8], with modifications.
According to MS-TW, the diagnosis of MS is made
when at least three of the following five risk determi-
nants are present: waist circumference≥ 90 cm in men
and≥ 80 cm in women; blood pressure> 130/85 mmHg or
patient is taking antihypertensive medications; high-density
lipoprotein cholesterol (HDL-C) < 0.9 mM in men
and<1.03 mM in women; fasting plasma glucose≥ 5.6 mM
or patient is undergoing regular treatment for diabetes
mellitus; and triglyceride level≥1.70 mM. Nevertheless, it
would be useful if a simpler index is available for easy diag-
nosis of individuals at risk of MS in clinical settings.
Recently, Kahn proposed the use of lipid accumula-
tion product (LAP), a novel index of central lipid accu-
mulation, to predict the risk of MS [9]. LAP is based
on a combination of waist circumference and plasma
triglyceride levels. The LAP method was shown to pre-
dict diabetes [10] and recognize cardiovascular risk [11]tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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LAP was also associated with all-cause mortality in
non-diabetic patients at high cardiovascular risk [12]
and all-cause, cardiovascular, and congestive heart fail-
ure mortality in postmenopausal women [13]. In
addition, LAP has been tested in the Chinese popula-
tion for predicting diabetes. Analysis of areas under the
curves (AUCs) for receiver-operating characteristic
(ROC) curves indicated that LAP was able to predict
diabetes better than waist-to-hip ratio, waist circumfer-
ence, and BMI, in both men and women [14]. LAP has
also been applied to healthy Argentinian men, with an
AUC of 0.91 observed for MS [15]. With Taiwanese
people, we conducted a cross-sectional study to assess
the accuracy of LAP employing a number of adiposity
measures. The adiposity measures included BMI, waist
circumference, hip circumference, waist-to-hip ratio,
and waist-to-height ratio, central obesity (defined as
waist circumference ≥ 90 cm in males and ≥ 80 cm in
females), and body adiposity index [8].
Methods
Study subjects
Study subjects were individuals recruited from a physical
examination center at a regional hospital in southern
Taiwan between May 2007 and April 2008. The study
was approved by the Institutional Review Board of the
hospital, and written informed consent was provided by
all participants before enrollment.
Demographic information and clinical measurements
Demographic information including age, sex, body
weight, height, waist circumference, and hip circumfer-
ence of the subjects was recorded. Waist circumference
was measured at the umbilicus (with thin clothes worn),
and hip circumference measured around the widest por-
tion of the buttocks [16]. Subjects who were below
50 years or on lipid-lowering medications were excluded
from the study. BMI was calculated by dividing weight
(in kilograms) by the square of the height (in meters).
Waist-to-hip and waist-to-height ratios, expressed as
percentages, were determined by dividing waist circum-
ference, respectively, by hip circumference or body
height.
Clinical characteristics including sitting blood pres-
sure, total cholesterol, HDL-C, triglyceride, and history
of hypertension were also recorded. Blood samples were
collected from each subject after a minimum eight-hour
fasting period. Total cholesterol, HDL-C, triglyceride,
and glucose were analyzed using an auto-analyzer (Sys-
mex XE-2100 Blood Cell Analyzer, Kobe, Japan).
Central obesity was defined as a waist circum-
ference ≥ 90 cm in males and ≥ 80 cm in females. Body
adiposity index (BAI) was calculated according to themethod of Bergman and colleagues, where BAI = ((hip
circumference [cm])/((height [m])1.5)− 18) [17]. The
LAP was calculated as (waist circumference [cm] − 65) ×
(triglyceride concentration [mM]) for men, and (waist
circumference [cm] − 58) × (triglyceride concentration
[mM]) for women [11]. The formula includes the mini-
mum sex-specific waist circumference values of 65 and
58 cm, for men and women, respectively [9]. In our sam-
ple, the minimum waist circumference values for men
(62 cm) and women (61 cm) were approximately 5% dif-
ferent to those used in the original equation for the def-
inition of LAP. MS-TW was defined in this study
according to MS criteria for Taiwanese people [18].Statistical analyses
Statistical analysis was performed using R software, ver-
sion 2.12.1 (Free Software Foundation, Inc., Boston, MA,
U.S.A.). A two-sided P value ≤ 0.05 was considered sta-
tistically significant. Summary data are represented as
mean ± SD for continuous variables, and frequency and
percentage for categorical variables. Simple logistic re-
gression analysis was performed to test associations be-
tween MS-TW and various adiposity measures including
LAP, waist-to-height ratio, BMI, waist circumference,
central obesity, waist-to-hip ratio, and body adiposity
index. A ROC analysis was conducted for each adiposity
measures to evaluate their ability to correctly discrimin-
ate MS-TW. Plots of the sensitivity (true positive) versus
1− specificity (false positive) were made and the overall
diagnostic accuracy was quantified using AUCs. Values
for each AUC can be between 0 and 1, with values
greater than 0.5 desirable. A value of 1 signifies perfect
diagnostic accuracy. A parameter possesses accurate
diagnostic sensibility when the AUC value is greater than
0.75 [19].
AUCs of the adiposity measures were ranked in de-
creasing order of their values and then the adiposity
measure that exhibited the greatest AUC value was com-
pared with the next highest AUC value, and so on. Com-
parisons were made by applying the ROC test of
DeLong using the roc.test function of the pROC library
in R. Sensitivity, specificity, along with positive and
negative predictive values were also estimated. The opti-
mal cut-off was calculated as the minimum value of the
square root of [(1 − sensitivity)2 + (1 − specificity)2] [20],
using the pROC coords function with the “closest.
topleft” option selected.Results
Basic characteristics for the 513 study subjects are pre-
sented in Table 1. The mean age of subjects was
59.1 ± 7.0 years. Around 20.5% of subjects were classified
as having MS according to MS-TW criteria, with no
Table 1 Basic characteristics of study subjects (n=513)
Variable Mean Male (n=266) Female (n=247) P
Age (years) 59.1 ± 7.0 59.3 ± 6.9* 58.8 ± 7.0 0.226
Hypertension, n (%) 146 (28.5) 85 (32.0) 61(24.7) 0.069
Diabetes, n (%) 49 (9.6) 28 (10.5) 21 (8.5) 0.436
Waist circumference (cm) 80.0 ± 8.6 84.0 ± 7.6 75.6 ± 7.3 < 0.001
Central obesity, n (%) 114 (22.2) 50 (18.8) 64 (25.9) 0.053
Hip circumference (cm) 92.5 ± 5.4 92.4 ± 5.3 92.6 ± 5.4 0.692
Waist-to-hip ratio (%) 86.4 ± 7.2 91.7 ± 5.4 81.7 ± 5.9 < 0.001
WHtR (%) 49.8 ± 4.9 50.6 ± 4.5 48.9 ± 5.1 < 0.001
BMI (kg/m2) 24.2 ± 3.0 24.5 ± 2.7 23.9 ± 3.0 0.005
Body adiposity index 27.6 ± 3.9 25.2 ± 2.7 30.1 ± 3.4 < 0.001
Systolic blood pressure (mmHg) 130 ± 19 128± 18 132± 20 0.007
Diastolic blood pressure (mmHg) 76 ± 12 79 ± 11 72 ± 12 < 0.001
Total cholesterol (mM) 5.09 ± 0.92 4.97 ± 0.96 5.21 ± 0.85 0.001
Total cholesterol≥ 6.22 mM, n (%) 52 (10.1) 21 (7.9) 31 (12.6) 0.081
HDL-C (mM) 1.40 ± 0.39 1.28 ± 0.36 1.52 ± 0.39 < 0.001
HDL-C< 0.9 mM in men or < 1.03 mM in women, n (%) 128 (25.0) 54 (20.3) 74 (30.0) 0.012
Triglyceride (mM) 1.33 ± 0.78 1.42 ± 0.85 1.22 ± 0.70 0.002
Triglyceride≥ 1.70 mM, n (%) 121 (23.6) 70 (26.3) 51 (20.6) 0.131
Fasting glucose (mM) 5.25 ± 1.08 5.29 ± 1.10 5.19 ± 1.05 0.127
Fasting glucose≥ 5.6 mM, n (%) 95 (18.5) 56 (21.1) 39 (15.8) 0.125
MS-TW, n (%) 105 (20.5) 52 (19.5) 53 (21.5) 0.592
LAP 25.9 ± 21.6 23.0 ± 23.2 28.6 ± 19.3 0.001
*Values are mean ± standard deviation except otherwise denoted.
Central obesity: waist circumference≥ 90 cm in males and≥ 80 cm in females.
Body adiposity index: (hip circumference/height1.5)− 18.
Hypertension: subjects with a history of hypertension or using antihypertensive medications.
HDL-C high-density lipoprotein cholesterol, MS-TW: metabolic syndrome criteria for Taiwanese, WHtR waist-to-height ratio, BMI body mass index, LAP lipid
accumulation product.
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and females.
Male subjects had significantly greater waist circum-
ferences, waist-to-hip and waist-to-height ratios, BMIs,
diastolic blood pressure, and triglyceride levels com-
pared with female subjects. However, female subjects
had significantly higher body adiposity indices, systolic
blood pressure, total cholesterol, HDL-C levels, and LAP
compared with male subjects.
Simple logistic regression analysis indicated that all
adiposity measures were significantly associated with
MS-TW (Table 2). Regarding the diagnostic accuracy for
MS-TW, LAP showed the highest AUC value (0.90; 95%
CI, 0.87–0.93), followed by waist-to-height ratio (0.81;
95% CI, 0.77–0.86). The AUC for LAP was significantly
higher than that of the waist-to-height ratio (P < 0.001).
The AUC corresponding to waist-to-height ratio was sig-
nificantly higher than that for BMI (P= 0.040). There
were no significant differences between the remaining
adiposity measures and AUCs. ROC curves with thethree highest AUC values were plotted and presented in
Figure 1. The codes for calculating the probability of MS
in R, Microsoft Excel, or OpenOffice Calc are provided
in Additional File 1.
Because there were significant differences in LAP be-
tween sexes, logistic regression and ROC curve analyses
were conducted separately for males and females
(Table 2). The greatest AUC value for LAP was 0.92
(95% CI, 0.88–0.95) and 0.90 (95% CI, 0.86–0.95) in
males and females, respectively. There were no signifi-
cant differences between all comparisons of AUCs for
adiposity measures in either sex except that the AUC for
LAP was significantly higher than that for waist-to-
height ratio in both males (P= 0.004) and females
(P= 0.003).
ROC curve analyses revealed that the optimal cut-off
value for LAP was 28.4 with a sensitivity of 85% (95%
CI, 76–91%), a specificity of 83% (95% CI, 79–87%), a
positive predictive value (PPV) of 57% (95% CI, 49–
65%), a negative predictive value (NPV) of 96% (95%
Table 2 Simple logistic regression and AUC values for adiposity measures of MS using Taiwanese criteria (MS-TW)
Adiposity measure Odds ratio (95% CI) Area under curve (95% CI)
Total Male Female Total Male Female
LAP 1.09 (1.08–1.12) 1.10 (1.07–1.13) 1.12 (1.08–1.15) 0.901a (0.870–0.932) 0.916c (0.880–0.953) 0.901d (0.855–0.946)
WHtR (%) 1.32 (1.24–1.41) 1.40 (1.27–1.56) 1.28 (1.19–1.40) 0.813b (0.767–0.860) 0.827 (0.762–0.892) 0.819 (0.755–0.883)
BMI (kg/m2) 1.45 (1.33–1.59) 1.49 (1.31–1.72) 1.43 (1.27–1.63) 0.780 (0.733–0.827) 0.776 (0.709–0.844) 0.793 (0.726–0.859)
Waist circumference (cm) 1.14 (1.10–1.17) 1.21 (1.15–1.29) 1.20 (1.14–1.27) 0.766 (0.715–0.816) 0.825 (0.760–0.890) 0.817 (0.755–0.879)
Central obesity 11.90 (7.32–19.69) 17.42 (8.48–37.32) 8.68 (4.47–17.32) 0.749 (0.700–0.799) 0.766 (0.696–0.835) 0.731 (0.661–0.802)
BMI≥ 25 (kg/m2) 6.60 (4.13–10.79) 5.79 (2.98–11.90) 8.12 (4.20–16.36) 0.720 (0.672–0.768) 0.704 (0.637–0.772) 0.738 (0.669–0.807)
Waist-to-hip ratio (%) 1.12 (1.09–1.16) 1.27 (1.18–1.37) 1.20 (1.13–1.28) 0.699 (0.643–0.754) 0.784 (0.715–0.852) 0.784 (0.720–0.849)
Body adiposity index 1.16 (1.10–1.23) 1.30 (1.16–1.48) 1.24 (1.13–1.37) 0.670 (0.614–0.725) 0.726 (0.653–0.799) 0.715 (0.637–0.794)
LAP lipid accumulation product, WHtR waist-to-height ratio, BMI body mass index, AUC area under the curve.
Central obesity: waist circumference≥ 90 cm in males and≥ 80 cm in females.
Body adiposity index: (hip circumference/height1.5)− 18.
Odds ratios for all adiposity measures were significant at P< 0.001.
aP< 0.001 between the AUC value for LAP and that of the WHtR.
bP= 0.040 between the AUC value for WHtR and that of BMI.
cP= 0.004 between the AUC value for LAP and that of the WHtR.
dP= 0.004 between the AUC value for LAP and that of the WHtR.
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MS of 0.84.
In males, the optimal cut-off value for LAP was 31.6
with sensitivity of 88% (95% CI, 77–96%), specificity of
82% (95% CI, 76–87%), PPV of 55% (95% CI, 44–66%),
NPV of 97% (95% CI, 93–99%) and an AUC of 0.84 for
the prediction of MS. In females, the optimal cut-off
value for LAP was also 31.6, with a sensitivity of 66%
(95% CI, 52–78%), specificity of 93% (95% CI, 88–96%),
PPV of 71% (95% CI, 57–83%), NPV of 91% (95% CI, 86–
95%) and an AUC value of 0.87 for the prediction of MS.
Discussion
We are the first to report that LAP has strong predictive
accuracy, with an AUC of 0.90, for diagnosing MS inFigure 1 ROC curves for adiposity measures in predicting MS
using Taiwanese criteria (MS-TW). ROC, receiver-operating
characteristic; AUC, area under the curve; LAP, lipid accumulation
product; WHtR, waist-to-height ratio; BMI, body mass index;
MS, metabolic syndrome.Taiwanese people. LAP is a simple indicator that
requires only the determination of circulating triglycer-
ides and measurement of waist circumference. Although
waist-to-height ratio requires only a single anthropomet-
ric measurement of waist and height, the use of LAP as
a predictor of MS is more advantageous. Waist circum-
ference is unable to distinguish between visceral adi-
pose tissue and subcutaneous adipose tissue. Visceral
adiposity is more strongly associated with cardiometa-
bolic risks compared with subcutaneous adipose tissue
[21]. Visceral adipose tissue adipocytes have a higher
rate of lipolysis and also produce more adipocyto-
kines, such as interleukin-6 and plasminogen activator
inhibitor-1 [22]. Therefore, it is important to include a
routinely applicable indicator for evaluation of visceral
adiposity. Triglyceride has been reported as a signifi-
cant correlate of visceral adipose tissue in healthy
men, even after controlling for abdominal subcutane-
ous adipose tissue [23]. Furthermore, the use of trigly-
ceride levels in combination with waist circumference,
termed hypertriglyceridemic waist, has been shown to
be able to identify individuals with the greatest
amount of visceral fat [24] and to be associated with
increased risk of MS [25], diabetes [26], and coronary
artery disease [27].
Our AUC results for LAP in MS were similar to those
previously reported, and indicate the usefulness of LAP
across different ethnic groups. The AUC for LAP in MS
was 0.91 in a cross-sectional study of 552 healthy Argen-
tinian men [15]. MS was defined using the revised diag-
nostic criteria of NCEP ATP III. Another study on 768
healthy Spanish adults also showed that LAP has the
highest diagnostic accuracy for MS defined using NCEP
ATP III and International Diabetes Federation criteria
Chiang and Koo BMC Cardiovascular Disorders 2012, 12:78 Page 5 of 6
http://www.biomedcentral.com/1471-2261/12/78[28]. Moreover, a study of 40 Nigerian geriatric males
reported an AUC of 0.937 for LAP in predicting MS [29].
There are some potential limitations regarding the in-
terpretation of our results. First, a cross-sectional design
was used. Future prospective studies examining MS
should consider incorporating the AUC value for LAP to
evaluate its utility in predicting MS and risks of cardio-
vascular diseases and diabetes. Second, the study results
are applicable only to Taiwanese people 50 years and
over. Third, individual lifestyle information, such as
smoking and alcohol use, was not ascertained. These
may potentially impact upon the association between
obesity and MS.
Conclusions
LAP was found to be an accurate and simple method for
predicting the risk of MS in Taiwanese people, and could
be effectively used by clinicians. This simple clinical tool
may help, in a primary care setting, to identify subjects
who require further biochemical evaluation.
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Additional file 1: Programming code in R, Microsoft Excel and
OpenOffice Calc for calculating the probability of metabolic
syndrome based on the logistic regression model of lipid
accumulation product.
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